Last reviewed · How we verify
NCT07069478
Cannabidiol (CBD) and Stress Response: Psychobiological Mechanisms
NA trial testing Stress Intervention in CBD in 125 participants. Currently enrolling.
30 November 2026
Quick facts
| Lead sponsor | University of Minnesota |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 125 |
| Start date | 1 June 2025 |
| Primary completion | 30 November 2026 |
| Estimated completion | 30 November 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Stress Intervention
Conditions studied
- CBD — all drugs for CBD →
- Cannabidiol — all drugs for Cannabidiol →
- Stress — all drugs for Stress →
- Acute Stress Reaction — all drugs for Acute Stress Reaction →
Sponsor
University of Minnesota
Who can join
Adults 21 to 70, any sex, with CBD or Cannabidiol. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to determine the effects of regular cannabidiol (CBD) use on the psychobiological mechanisms of the stress response. This will be achieved by comparing acute stress responses of adults who either use or do not use CBD regularly. Correlates of CBD use, including tobacco use, will be collected.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07069478
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for CBD
Currently open trials in the same condition.
- NCT07001930 — Effects of Cannabidiol on Stress and Nicotine Withdrawal · Phase 1 · recruiting
- NCT05956834 — A Multi-Modal Remote Monitoring Platform for Frontotemporal Lobar Degeneration (FTLD) Syndromes · active not recruiting
- NCT04482244 — RCT of CBD for Anxiety in Advanced Breast Cancer · Phase 2 · active not recruiting
- NCT04778644 — Hippocampal Response to Acute Oral Doses of CBD During an fMRI Memory Task · Phase 1, PHASE2 · active not recruiting
- NCT04398719 — CBD-Microglia PET Study · EARLY_PHASE1 · recruiting
Other University of Minnesota trials
Trials by the same sponsor.
- NCT02421497 — MRI Technical Development and Applications in Kidney Disease · not yet recruiting
- NCT04100109 — Evaluating the Metabolic Effects of Polylactose: A Novel Prebiotic · NA · withdrawn
- NCT05454306 — Anser Clavicle Pin for Surgical Management of Midshaft Clavicle Fractures · NA · withdrawn
- NCT03192007 — Multi-Parametric MRI for Renal Transplantation · not yet recruiting
- NCT04940533 — Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07069478 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Minnesota
- Last refreshed: 16 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07069478.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing